Last chance! I'm a personal trainer, and my favorite recovery tool just dropped by $200 in the Prime Day sales
You know, like, actually having to do something about my achy muscles. I know, guilty as charged.
But that's the beauty of the hugely popular Hyperice Normatec 3. The leg 'massager' is so much more than that. It delivers dynamic air compression to help boost recovery, maximize performance and reduce muscular fatigue, all while you sit and do, well, nothing.
Elite athletes are using it, and I'll say this with my chest: it's epic. But you guessed it, it's also costly, which is why Prime Day is the perfect opportunity to pounce.
Right now, you can get the Hyperice Normatec 3 for $100 off at Hyperice if you choose the legs-only option or on sale for $200 off at Amazon if you choose the whole recovery system.
The kit is full-body, including legs, hips and arms, and comes FSA-HSA-approved. You can save money by opting for just legs and hips for $920, or you can shop the 'just legs' option for $799.
The Hyperice Normatec 3 is an advanced recovery tool that might cost you a bit upfront, but saves you down the line. No massage therapist fees in sight.
Let's get the specs out of the way first. The control unit weighs 3.2lbs and battery life lasts up to 3 hours. On Amazon, Normatec Legs (the legs-only device) is only available in standard, which is measured as a 31"-35" inseam, and the maximum thigh circumference is 30".
The leg attachments come with 7 compression levels and feature ZoneBoost technology, which means you can ask the device to go longer and firmer in sore or tight areas.
The Normatec 3 uses air compression to help your muscles recover faster by increasing circulation and reducing swelling. The device also uses a patented Pulse technology to aid precision using 5 overlapping zones, and it uses biomimicry, which, according to Hyperice, replicates the "natural muscle pumps and one-way valves of the legs."
If you're not already sold, there's even a Hyperice App, and you can level up with the hips and arms features for a full-body experience.
From my experience, the compressions can feel quite intense, but once you adjust to them, it is deeply relaxing. All you need to do is sit back and get your favorite Netflix show ready.
You might need help strapping in if you use the entire kit!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures
DALLAS, July 24, 2025 (GLOBE NEWSWIRE) — Upsize Clinic, a leading provider of non-surgical male enhancement treatments, announces the opening of its newest clinic location in Dallas at 5232 Forest Lane, Suite 170. The clinic, led by board-certified physician Dr. Brad Sellers, offers the company's proprietary Upsize™ and Firm-X™ procedures, providing men in the Dallas-Fort Worth metroplex access to clinically proven, minimally invasive male enhancement procedures. The new Dallas location represents Upsize's continued national expansion, following the company's recent milestone of surpassing 1,500 successful procedures across its network of 20 affiliated physicians nationwide. The clinic specializes in two groundbreaking treatments: the Upsize™ procedure utilizing hyaluronic acid dermal fillers for girth enhancement, and the Firm-X™ treatment employing neuromodulator injections for improved function and appearance. 'Dallas men now have access to safe, effective enhancement options that deliver immediate results without the risks and downtime associated with surgical procedures,' said Dr. Brad Sellers, Medical Director of Upsize Dallas. 'These innovative treatments represent a significant advancement in male aesthetic medicine, offering natural-looking results that boost confidence and improve quality of life.' About Dr. Brad Sellers Dr. Sellers brings over two decades of medical expertise to his practice, having served as Medical Director and Associate Medical Director at several prominent Dallas-area Emergency Departments and Level 1 and Level 2 Trauma Centers. His extensive background in emergency medicine, combined with his Certified Physician Executive credentials from the American Association of Physician Leaders, ensures the highest standards of patient safety and care. Recently completing specialized training in male enhancement procedures through Upsize LLC, as well as neurotoxin and dermal filler certification from the National Laser Institute, Dr. Sellers has expanded his practice to focus on intimate wellness and aesthetic treatments for men. His commitment to excellence and patient-centered approach makes him uniquely qualified to deliver these innovative procedures. The Upsize™ Procedure: Non-Surgical Girth Enhancement The flagship Upsize™ procedure uses FDA-approved hyaluronic acid dermal fillers (used off-label) administered via micro-cannula to achieve natural girth enlargement and improved symmetry. Key benefits include: Immediate Results : Patients see enhancement immediately following the 30-minute in-office procedure : Patients see enhancement immediately following the 30-minute in-office procedure Minimal Downtime : Most men return to normal activities within days : Most men return to normal activities within days Reversible Option : Results can be adjusted or reversed if desired : Results can be adjusted or reversed if desired Natural Feel : Maintains natural texture and sensation : Maintains natural texture and sensation Long-Lasting: Results typically last an average of 24 months Firm-X™: Revolutionary Neuromodulator Treatment The innovative Firm-X™ treatment utilizes neurotoxin injections to enhance male sexual health and appearance. This procedure works by relaxing smooth muscles in corpus cavernosum vasculature, leading to: Enhanced blood flow and circulation Reduced retraction for a fuller appearance Improvements in erectile dysfunction The treatment involves strategic placement of 100 units of neuromodulator through four injection points, with the entire procedure completed in under 30 minutes. Meeting Growing Demand for Male Enhancement The opening of Upsize Dallas addresses increasing demand for physician administered male aesthetic treatments in North Texas. As men become more comfortable seeking enhancement options, the need for safe, effective alternatives to risky surgeries and unregulated products has grown significantly. 'Men seeking enhancement deserve access to clinically proven treatments performed by qualified medical doctors,' Dr. Sellers noted. 'Our procedures offer a discreet, professional solution that prioritizes both results and safety.' Comprehensive Patient Care The Dallas clinic provides confidential consultations where patients can discuss their options and determine the most appropriate treatment plan. Both procedures are performed in a discrete, medical-grade facility with strict adherence to safety protocols. Patients receive lifetime follow-up care at no additional charge, ensuring ongoing support and satisfaction. About Upsize LLC Headquartered in Roseville, California, Upsize LLC specializes in minimally invasive male enhancement treatments. The company's proprietary procedures have earned recognition for their safety profile, immediate results, and high patient satisfaction rates. With locations across California, Texas, Florida, New York, New Jersey, Ohio, Arizona, Nebraska, and international expansion into Panama and Canada, Upsize continues to lead innovation in male aesthetic medicine. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Vogue
2 hours ago
- Vogue
8 Best Pore Strips for a Congestion-Free T-Zone
When it comes to quick fixes for clogged pores, the best pore strips have long held a beloved spot in skin-care routines worldwide. There's something undeniably satisfying about peeling away a strip and seeing the visible evidence of impurities (think: blackheads and sebaceous filaments) lifted from your skin. Beyond their instant gratification, pore strips provide an effective way to deep-clean areas prone to blackheads, such as the nose, chin, and forehead. They act like a magnet, drawing out excess oil and debris that can clog pores and lead to breakouts. In the age of TikTok skin-care experts, pore strips have gotten a bad rep—but you don't have to toss away the category as a whole. 'Using pore strips occasionally isn't harmful, but frequent use can sometimes irritate the skin,' says board certified dermatologist Dr. Dara Spearman. Plus, the pore strips of 2025 are a far cry from their Y2K predecessors, which tore off skin with a vengeance—evolution in the category has led to gentler hydrocolloid and biocellulose patches that equally, if not more effective. Meanwhile, K-beauty alternatives offer sebum-melting oils and treatments that ditch adhesive patches altogether. Dr. Spearman adds, 'While traditional strips provide quick results, K-beauty techniques offer a gentler, long-term way to care for your pores. It really comes down to what works best for your skin.' Vogue's Favorite Sheet Masks In This Story While pore strips aren't a comprehensive solution for long-term skin health, their benefits as a targeted, affordable, and satisfying cleansing method remaining clear in between proper facial appointments—particularly when combined with consistent skin-care routines. Scroll to discover our favorite blackhead-beating nose and T-zone strips to unclog pores and leave skin feeling fresh. Best Hydrocolloid: Mighty Patch Nose Strips Mighty Patch Nose Strips $17 AMAZON
Business Upturn
2 hours ago
- Business Upturn
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
